Cianidanol
drugOn this page
Also known as Catechind-Catechinic acidCatechuic acidCatergenD-catecholNSC-2819(+)-catechinD-Catechin3S-(+)CatechinSID11113249SID26753531SID50105958SID85231341SID90341637D-(+)-catechinSID69414cathechin(2R,3S)-catechin
Summary
Cianidanol (CHEMBL311498) is an approved small-molecule antioxidant.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Clinical trials: 13
- Chemistry: 290.27 Da · C15H14O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL311498 |
| Name | Cianidanol |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 9064 |
| ChEBI | CHEBI:15600 |
| Molecular formula | C15H14O6 |
| Molecular weight | 290.27 |
| InChIKey | PFTAWBLQPZVEMU-DZGCQCFKSA-N |
SMILES: C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O
IUPAC name: (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
ChEBI definition: The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.
Pharmacological roles (ChEBI): antioxidant.
Other ChEBI roles (chemical / environmental): plant metabolite.
Also known as: Catechin, d-, Catechinic acid, Catechuic acid, Catergen, Cianidanol, D-catechol, NSC-2819, (+)-catechin, (+)-Catechin, D-Catechin, 3S-(+)Catechin
Parent form; salt/anhydrous children: CHEMBL1256783
Patent coverage: 33,031 distinct patent families (59,647 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 58,774 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 23 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Survival motor neuron protein, ATP-dependent DNA helicase Q1, RecQ-like DNA helicase BLM, Peripheral myelin protein 22, Melatonin receptor type 1A, Melatonin receptor type 1B, Prothrombin, Prostaglandin G/H synthase 1.
Bioactivity
ChEMBL activities: 6 potent at pChembl ≥ 5 of 34 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| C7FF04 | 7.22 | IC50 | 60 | nM | CHEMBL_ACT_26043004 |
| C7FF04 | 7.16 | IC50 | 70 | nM | CHEMBL_ACT_26043017 |
| Q63921 | 5.83 | AC50 | 1490 | nM | CHEMBL_ACT_25174275 |
| SOST | 5.8 | Kd | 1579 | nM | CHEMBL_ACT_25835120 |
| SOST | 5.73 | Kd | 1845 | nM | CHEMBL_ACT_25835129 |
| P05979 | 5.39 | IC50 | 4100 | nM | CHEMBL_ACT_2429561 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 13.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 8 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07149506 | PHASE3 | ENROLLING_BY_INVITATION | Oral or Topical Catechins for Radiation Dermatitis |
| NCT01690676 | PHASE2 | COMPLETED | Effect of an Apple Polyphenol Extract on Brachial Artery Flow-mediated Vasodilatory Function |
| NCT02964377 | PHASE1/PHASE2 | COMPLETED | Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents |
| NCT02656212 | PHASE1 | COMPLETED | Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2) |
| NCT02292342 | EARLY_PHASE1 | COMPLETED | An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men |
| NCT06631820 | Not specified | RECRUITING | The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD |
| NCT00377507 | Not specified | TERMINATED | Catechin Mouth-washing for Removal of Intraoral Bacteria |
| NCT00448513 | Not specified | COMPLETED | Effects of Tea Catechin Extracts on Oxidative Damage |
| NCT01097226 | Not specified | COMPLETED | Bioavailability and Vascular Effects of Apple Polyphenols |
| NCT01691404 | Not specified | COMPLETED | Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO) |
| NCT02221791 | Not specified | COMPLETED | Comparison of Pure Epicatechin and Cocoa on Markers of Vascular Function |
| NCT02408289 | Not specified | COMPLETED | The Randomized Controlled Cocoa-Appetite Trial |
| NCT02898571 | Not specified | UNKNOWN | Cross-over Double-blind Intervention to Investigate the Effects of Defined Antioxidant-containing Drinks on Time Course of Antioxidant Capacity |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.